申请人:BRISTOL-MYERS SQUIBB COMPANY
公开号:EP0618221A2
公开(公告)日:1994-10-05
Inhibition of farnesyl protein transferase is effected by compounds of the formula
its enantiomers, diastereomers, pharmaceutically acceptable salts, prodrugs or solvates thereof, wherein:
A₁ and A₂ are each independently H, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, phenyl or substituted phenyl;
G₁ is S or O;
G₂ is H, -C(O)OH, -C(O)NH₂, 5-tetrazolyl, -C(O)N(R₇)OH or -CH₂OH;
X is O or R₈N;
Y and Z are each independently -CH₂- or -C(O)-;
R₁, R₂, R₃, R₄, R₅, R₆ and R₇ are each independently H or alkyl;
R₁ may also be alkanoyl,
R₁ and A₁ taken together may be -(CH₂)m;
R₈ is H, alkyl, phenyl, phenylalkyl, substituted phenyl, (substituted phenyl)alkyl or -C(O)R₉;
R₉ is H, alkyl, phenyl, phenylalkyl, substituted phenyl or (substituted phenyl)alkyl;
m is 3 or 4;
n is 0, 1 or 2;
p is 0, 1 or 2; and
q is 0 or 1, with the proviso that when p is 0, then q is also 0.
式中的化合物可抑制法尼基蛋白转移酶的作用
其对映体、非对映体、药学上可接受的盐、原药或溶液,其中
A₁ 和 A₂ 各自独立地为 H、烷基、取代烷基、环烷基、取代环烷基、苯基或取代苯基;
G₁ 是 S 或 O;
G₂ 是 H、-C(O)OH、-C(O)NH₂、5-四唑基、-C(O)N(R₇)OH 或 -CH₂OH;
X 是 O 或 R₈N;
Y 和 Z 各自独立地为 -CH₂- 或 -C(O)-;
R₁、R₂、R₃、R₄、R₅、R₆ 和 R₇ 各自独立地为 H 或烷基;
R₁ 也可以是烷酰基、
R₁ 和 A₁ 合在一起可以是-(CH₂)m;
R₈ 是 H、烷基、苯基、苯基烷基、取代苯基、(取代苯基)烷基或 -C(O)R₉;
R𠢙 是 H、烷基、苯基、苯基烷基、取代苯基或(取代苯基)烷基;
m 是 3 或 4
n 是 0、1 或 2
p 是 0、1 或 2;以及
q 为 0 或 1,但条件是当 p 为 0 时,q 也为 0。